Bergin K, Yuen F, Wallington‐Beddoe C, et al. - Among 39 patients suffering from relapsed/refractory multiple myeloma (RRMM) aged ≥ 18 years with one to three prior lines of therapy, this investigation was carried out to assess efficacy as well as tolerability of continuous ixazomib‐thalidomide‐dexamethasone (ITd: 4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly). An overall response rate of 56·4% with a clinical benefit rate of 71·8%, was reported. A median progression‐free survival of 13·8 months was achieved, and median overall survival was not reached. In 7·7% and 20·6% of patients, occurrence of grade 3/4 haematological and non‐haematological adverse events was noted, respectively. There was a need for ITd dose decreases in 15·4%, 48·7% and 35·9% of patients respectively. Overall, ITd was shown to have promising effectiveness as well as tolerability as an affordable all‐oral PI‐IMID approach for RRMM.